
CLAIMS

1. Use of a compound of structural formula (II):



(II),

or a pharmaceutically acceptable salt thereof, for the manufacture of a medication for treating a malignancy that is positive for Epstein Barr Virus (EBV), wherein:

L^7 is a bond, unsubstituted alkylene or unsubstituted heteroalkylene

$R^{3.2}$ is halogen;

$R^{3.3}$ is halogen;









R^4 is–$CX^{4.1}_3$, –CN, or unsubstituted C_1-C_4 alkyl;


R^7 is hydrogen, –$C(O)R^{7D}$, –$C(O)NR^{7B}R^{7C}$, –OR^{7A}, -$NR^{7B}C(O)R^{7D}$, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl;


R^{7A}, R^{7B}, $R^{7.2B}$, R^{7C}, and R^{7D}, are independently hydrogen, or substituted or unsubstituted alkyl; and


$X^{4.1}$, is –Cl, –Br, –I or –F.


2. The use of claim 1, wherein the compound is:














,


,


,


,


, or


or a pharmaceutically acceptable salt thereof.

3. The use of claim 1, wherein the EBV positive malignancy is Burkitt's lymphoma, Hodgkin's lymphoma, diffuse large B-cell lymphoma, NK/T-cell lymphoma, cutaneous T-cell lymphoma, nasopharyngeal carcinoma, gastric cancer, vulvar squamous cell carcinoma, salivary gland cancer, orbit choroidal melanoma, or adenocarcinoma consistent with pancreaticobiliary.

4. The use of claim 3, further comprising a chemotherapeutic agent or anticancer agent.

5. The use of claim 4 , wherein the chemotherapeutic agent or anticancer agent is an antiproliferative/antineoplastic drug, an antimetabolite, an antitumor antibiotic, an antimitotic agent, a topoisomerase inhibitor, a cytostatic agent, an estrogen receptor down regulator, an antiandrogen, a LHRH antagonist or LHRH agonist, a progestogen, an aromatase inhibitor, an inhibitor of 5-alpha-reductase, an agent which inhibits cancer cell invasion, an inhibitor of growth factor function, a farnesyl transferase inhibitor, a tyrosine kinase inhibitor, a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family, an inhibitor of the platelet-derived growth factor family, an inhibitor of the hepatocyte growth factor family; an antiangiogenic agent, a vascular damaging agent, an antisense therapy agent, an anti-*ras* antisense agent, an gene therapy agent, or an immunotherapeutic agent.

6. The use of claim 5, wherein the chemotherapeutic agent or anticancer agent is an anti-proliferative agent, a chemotherapeutic agent, an antimetabolite, an antimicrotubule agent, an alkylating agent, a platinum agent, an anthracycline, an antitumor antibiotic, a topoisomerase inhibitor, a purine antagonist, a pyrimidine antagonist, a cell maturing agent, a DNA repair enzyme inhibitor, an enzyme that prevents cell survival, a histone deacetylase inhibitor, a cytotoxic agent, a hormone, an immuno-modulator, a Bcr-Abl kinase inhibitor, a hormone agonist or antagonist, partial agonist or partial antagonist, a kinase inhibitor, surgery, radiotherapy, an endocrine therapy, a biological response modifier, a hyperthermial agent, a cryotherapeutic agent, an immuomodulating agent, an agent to attenuate any adverse effects, a spindle poison, a podophyllotoxin, an antibiotic, or a nitrosourea.

7. The use of claim 6, wherein the antimetabolite is 5-fluoro uracil, methotrexate, azacitidine, decitabine, fludarabine or cytarabine.

8. The use of claim 6, wherein the antimicrotubule agent is a vinca alkaloid or a taxane.

9. The use of claim 6, wherein the alkylating agent is mechlorethamine, chlorambucil, cyclophosphamide, melphalan, carmustine, lomustine, ifosfamide, carmustine, busulfan, cyclophosphamide, dacarbazine, ifosfamide, bischloroethylnitrosurea or hydroxyurea.

10. The use of claim 6, wherein the platinum agent is cisplatin, carboplatin, oxaliplatin, satraplatin (JM-216) or CI-973.

11. The use of claim 5, wherein the chemotherapeutic agent or anticancer agent is an immunomodulating agent.

12. The use of claim 1, wherein R^4 is $–CX^{4.1}{}_3$, –CN, or methyl.